Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alpha1-antitrypsin for Neuromyelitis Optica attacks
NCT02087813Phase 1Withdrawn
- Sponsor
- Stanford University
- Start
- Mar 2014
- Primary completion
- Mar 2016
- Countries
- 1
01
Overview
Phase 1, open-label trial of alpha-1-proteinase inhibitor in neuromyelitis optica (NMO), sponsored by Stanford University. Primary endpoint: Opticospinal Impairment Score at 24 weeks. Planned start Mar 2014; status: withdrawn.
02
Drugs
alpha-1-proteinase inhibitor
03
Conditions
neuromyelitis optica (NMO)
Beyond the preview
Go deeper on NCT02087813.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02087813.